THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

Save this PDF as:

Size: px
Start display at page:

Download "400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC"

Transcription

1 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS LVFX 500 mg Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX mg C. trachomatis 17 M. genitalium 4 C. trachomatis M. genitalium % 19/22 C. trachomatis M. genitalium C. trachomatis M. genitalium 94.1% 16/ % 2/4 100% 1/ % 20/22 C. trachomatis M. genitalium C. trachomatis M. genitalium 100% 17/ % 2/4 100% 1/1 M. genitalium P LVFX 500 mg

2 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC Cmax/MIC 1 AUC Cmax LVFX 500 mg1 1 Mycoplasma genitalium LVFX 500 mg 1 1 2,3 LVFX 500 mg I C. trachomatis M. genitalium 1 2 mg/dl mg LVFX 500 mg 250 mg LVFX 250 mg mg mg 2 1 1

3 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS G-CSF NSAID 2 5. Fig. 1 1 STI Fig. 1.

4 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec C. trachomatis TMA, SDA, PCR Neisseria gonorrhoeae, M. genitalium PCR 4 5 AST GOT ALT GPT -GTP LDH ALPCK CPK BUN Na, K, Cl CRP C. trachomatis M. genitalium 2

5 Table 1. Dec THE JAPANESE JOURNAL OF ANTIBIOTICS

6 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec C. trachomatis M. genitalium C. trachomatis M. genitalium % II C. trachomatis M. genitalium Table 1 22 C. trachomatis 17 M. genitalium 4 C. trachomatis M. genitalium STI /hpf 1000 Table 2.

7 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS /hpf 1000 C. trachomatis M. genitalium Table 2 C. trachomatis 17 C. trachomatis 15 C. trachomatis Ureaplasma parvum C. trachomatis Ureaplasma urealyticum 1 M. genitalium 4 M. genitalium 3 M. genitalium U. urealyticum 1 C. trachomatis M. genitalium C. trachomatis M. genitalium U. parvum Table % 19/22 C. trachomatis M. genitalium C. trachomatis M. genitalium 94.1% 16/ % 2/4 100% 1/1 3 P % 18/22 Table 4 C. trachomatis M. genitalium C. trachomatis M. genitalium82.4% 14/ % 3/4 100% 1/1 P Table % 20/22 C. trachomatis M. genitalium C. trachomatis M. genitalium 100% 17/ % 2/4 100% 1/1 M. genitalium P % 21/22 C. trachomatis M. genitalium C. trachomatis M. genitalium 100% 17/ % 3/4 Table Table 4.

8 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec Table Table % 1/1 P III. C. trachomatis M. genitalium LVFX 500 mg 1 1 C. trachomatis % 16/17 100% 17/17 C. trachomatis LVFX 500 mg S. TAKAHASHI 6 M. genitalium % 2/4 50.0% 2/4 C. trachomatis M. genitalium C. trachomatis M. genitalium M. genitalium 7 LVFX 100 mg 3 / M. genitalium % 4/ % 8/16 8 LVFX M. genitalium

9 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS mg 1 1 M. genitalium LVFX MIC g/ml % C. trachomatis 1 C. trachomatis 2 4 C. trachomatis PCR C. trachomatis 2 4 PCR PCR M. genitalium 2 M. genitalium M. genitalium 2 4 M. genitalium LVFX 500 mg mg 500 mg 22 LVFX 500 mg % 482/29, % 203/ 16, LVFX 500 mg1 1 C. trachomatis LVFX 500 mg M. genitalium 4 LVFX : 57 60, Levo oxacin 500 mg S-2 : 34 46, ZHANG, Y. Y.; H. H. HUANG, Z. Y. REN, et al.: Clinical evaluation of oral levo oxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China. J. Infect. Chemother. 15: , YOSHIDA, T.; S. MAEDA, T. DEGUCHI, et al.: Phylogeny-based rapid identification of Mycoplasma and Ureaplasma from urethritis. J. Clin. Microbiol. 40: ,

10 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec : , TAKAHASHI, S.; K. ICHIHARA, J. HASHIMOTO, et al.: Clinical ef cacy of levo oxacin 500 mg once daily for 7 days for patients with nongonococcal urethritis. J. Infect. Chemother. 17: , : , M. genitalium M. genitalium 12: 74 78, HAMASUNA, R.; J. S. JENSEN & Y. OSADA: Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. Antimicrob. Agents Chemother. 53: , Polymerase Chain Reaction 13: 81 86, Levo oxacin 500 mg : , YAMAGUCHI, H.; H. KAWAI, T. MATSUMOTO, et al.: Post-marketing surveillance of the safety of levo oxacin in Japan. Chemotherapy 53: , 2007 Ef cacy and safety of levo oxacin to non-gonorrheal urethritis SHOICHI ONODERA Fuji City General Hospital YASUHIKO ONOE Miyamotocho Central Clinic TAKAHIDE HOSOBE Hosobe Clinic TETSURO KATO and MASAKI YOSHIDA Department of Infectious Diseases and Infection Control, The Jikei University School of Medicine We investigated the efficacy and safety of levofloxacin LVFX 500 mg once a day in patients with non-gonorrheal urethritis. Men, aged 20 years or older, with urethritis symptoms, and detection of Chlamydia trachomatis C. trachomatis or Mycoplasma genitalium M. genitalium by a microbiological examination were eligible for this study. Patients were administered LVFX 500 mg, orally, once a day and the dosage period was seven days. We assumed 22 patients for a safety and ef cacy analysis. In 22 patients, 17 patients had urethritis with C. trachomatis, 4 patients urethritis with M. genitalium, and one patient mixed infection of C. trachomatis and M. genitalium. In the clinial study, the primary endpoint was set as the bacteriological eradication rate at two to four weeks after completion of treatment. The

11 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS bacterial eradication rate in the urethritis was 86.4% 19/22. The bacterial eradication rate in the urethritis with C. trachomatis, M. genitalium, and mixed infection of C. trachomatis and M. genitalium were 94.1% 16/17, 50.0% 2/4, 100% 1/1, respectively. A signi cant difference was not recognized among the three groups. The clinical efficacy at two to four weeks after completion of treatment was 90.9% 20/22. The clinical ef cacy rates in the urethritis with C. trachomatis, M. genitalium, and mixed infection of C. trachomatis and M. genitalium were 100% 17/17, 50.0% 2/4, 100% 1/1, respectively. The efficacy rate of urethritis with M. genitalium was signi cantly low. No adverse drug reactions were observed. These results suggest that once-a-day levofloxacin 500 mg is effective and safe treatment for non-gonorrheal urethritis.

366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -

366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli - Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486

More information

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3- Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl) oxy]-14-ethyl-12,

More information

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration

More information

VOL.42 S-1

VOL.42 S-1 CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical

More information

日本化学療法学会雑誌第66巻第2号

日本化学療法学会雑誌第66巻第2号 173 Table 1.Detection rates of Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Ureaplasma urealyticum, Haemophilus influenzae and adenovirus from male urethritis in Urethritis No.

More information

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii

More information

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak

More information

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.

More information

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter

More information

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2

More information

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative

More information

semen quality or those without WBC in semen. In the patients with azoospermia and normal FSH levels (normogonadotropic azzospermia), the antibody (IgG

semen quality or those without WBC in semen. In the patients with azoospermia and normal FSH levels (normogonadotropic azzospermia), the antibody (IgG CLINICAL STUDIES OF UROGENITAL INFECTIONS WITH CHLAMYDIA TRACHOMA TIS Report 2. The Epidemiology of Chlamydial Infections in Okayama District in Japan and Detection of Antibodies to Chlamydiae in the Sera

More information

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,

More information

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin

More information

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of

More information

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin

More information

Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen

Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 53 53 Tebipenem pivoxil 1 1, 3 2 2 1 1 Meiji Seika 2 Meiji Seika G 3 Meiji Seika 2015 12 15 Tebipenem pivoxil 10% 2010 4 2013 3 3,547 3,540 3,540 3,331

More information

Table1MIC of BAY o 9867 against standard strains

Table1MIC of BAY o 9867 against standard strains Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative

More information

Table 1.Concentration of gatifloxacin (Middle-ear) Table 2.Concentration of gatifloxacin (Paranasal sinuses) Table 3.Concentration of gatifloxacin (Tonsil) Table 4.No.of patients studied Table 5.Background

More information

CHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative

More information

Fig. 1 Chemical structure of KW-1070

Fig. 1 Chemical structure of KW-1070 Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.

More information

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels

More information

Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s

Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s Vesical irritability without urinary Pain. Pyuria 10/

More information

CHEMOTHERAPY FEB Table 1 Background of volunteers

CHEMOTHERAPY FEB Table 1 Background of volunteers CHEMOTHERAPY FEB. 1985 Table 1 Background of volunteers Table 3 Reproducibility of saisomicln In the EIA and the RIA Fig.1 Comparison of the EIA with the RIA or bioassay of sisomicin Table 4 Blood levels

More information

Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.

More information

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella

More information

Table 1. Influence of urine ph on MBCs of new quinolones against Escherichia coli NIHJ JC-2 and Pseudomonas aeruginosa 18S; MBCs in urine were compared with those in Miieller-Hinton broth. Table 2. Influence

More information

日本化学療法学会雑誌第51巻第2号

日本化学療法学会雑誌第51巻第2号 piperacillin piperacillin PIPC. g Cmax CL PIPC CL CLR CLNR CL PIPC g g Cmax PIPC Key words: piperacillin Piperacillin PIPC PIPC g g PIPC Cmax g g ml g g ml g g ml T T T PIPC g g T Ccr ml min AUCCmax PIPC

More information

The clinical characteristics of Mycoplasma pneumoniae pneumonia in children younger than 6 years old Nobue Takeda1,2),Tomomichi Kurosaki1),Naruhiko Ishiwada2),Yoichi Kohno2) 1)Department of Pediatrics,Chiba

More information

1272 CHEMOTHERAPY MAR. 1975

1272 CHEMOTHERAPY MAR. 1975 1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides

More information

VOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence

More information

CHEMOTHERAPY MAY. 1988

CHEMOTHERAPY MAY. 1988 CHEMOTHERAPY MAY. 1988 CHEMOTHERAPY Fig. 1 Chemical structure CHEMOTHERAPY MAY. 1988 VOL.36 5-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY

More information

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover VOL.26 S-2 CHEMOTHERAPY Gentamicin (GM), Dibekacin (DKB), Tobramycin Fig. 1 Protein concentration and protein binding rate Table 2 Protein binding rate of PC-904 in serum of healthy adults, and patients

More information

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,

More information

Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood

Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba

More information

CHEMOTHERAPY APR. 1984

CHEMOTHERAPY APR. 1984 VOL.32 S-3 CHEMOTHERAPY dihydro-4-oxo-7-(1-piperazinyl)-1, 8-naphthyridine- CHEMOTHERAPY APR. 1984 VOL.32 S-3 CHEMOTHERAPY Table 1 Implantation rates and post- implantation survival rates in females mated

More information

1) i) Barber, M. et al.: Brit. Med J, 2, 565, 19'49. ii) Barber, M.F.G. J. Hayhoe and J. E. M. Whithead: Lancet, 1120 `1125, 1949.-2) Bergey: Bergey's Manual of Determinative Bacteriology 7 th Ed: (1958).-3)

More information

Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains

More information

CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation

CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation CHEMOTHERAPY CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation CHEMOTHERAPY Table 1 Preliminaly test of AM- 715 1): Mean } SD *: Significant difference

More information

日本化学療法学会雑誌第65巻第4号

日本化学療法学会雑誌第65巻第4号 Mycoplasma pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae Key words Mycoplasma pneumoniae Mycoplasma pneumoniae M. pneumoniae I M. pneumoniae M. pneumoniae M. pneumoniae

More information

Hisao Takayasu Department of Urology, Faculty of Medicine, University of Tokyo Masaaki Ohkoshi Department of Urology, Tokai University School of Medic

Hisao Takayasu Department of Urology, Faculty of Medicine, University of Tokyo Masaaki Ohkoshi Department of Urology, Tokai University School of Medic COMPARATIVE CLINICAL EFFECT OF AMIKACIN AND GENTAMICIN ON COMPLICATED URINARY TRACT INFECTIONS BY DOUBLE-BLIND METHOD Tsuneo Nishiura and Yukimichi Kawada Department of Urology, Gifu University School

More information

Table 1.Distribution and number of cases with acute upper respiratory tract infections classified according to antimicrobial agents administered Table 2. Distribution of cases which were enrolled to set

More information

Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil

More information

日本化学療法学会雑誌第59巻第5号

日本化学療法学会雑誌第59巻第5号 Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.

More information

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table

More information

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity

More information

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio 7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine

More information

名称未設定-1

名称未設定-1 Study on Clinical Factors Affecting the Fungal Culture Test - Relevance of Dry Mouth - Yoshiko YAMAMURA, Yukihiro MOMOTA, Hideyuki TAKANO, Koichi KANI, Katsumi MOTEGI, Fumihiro MATSUMOTO, Masayuki AZUMA

More information

CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection

More information

2 The Bulletin of Meiji University of Integrative Medicine 3, Yamashita 10 11

2 The Bulletin of Meiji University of Integrative Medicine 3, Yamashita 10 11 1-122013 1 2 1 2 20 2,000 2009 12 1 2 1,362 68.1 2009 1 1 9.5 1 2.2 3.6 0.82.9 1.0 0.2 2 4 3 1 2 4 3 Key words acupuncture and moxibustion Treatment with acupuncture, moxibustion and Anma-Massage-Shiatsu

More information

Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates

More information

48 皮 膚 第29巻 第1号 昭 和62年2月 第1-b図 第1-a図 第1図Micro Trak法 アッ 皮 細 胞 中あ るいは細 pin point sizeの による 胞 外に,アッ 粒子と 直 接 塗 抹 標本から プル グ リ ー ン に光 プル し てelelnentary る 粒子

48 皮 膚 第29巻 第1号 昭 和62年2月 第1-b図 第1-a図 第1図Micro Trak法 アッ 皮 細 胞 中あ るいは細 pin point sizeの による 胞 外に,アッ 粒子と 直 接 塗 抹 標本から プル グ リ ー ン に光 プル し てelelnentary る 粒子 Chlamydia trachomatis-syphilis-micro Trak Mariko SEISHIMA, M. D., Satoshi OKUMURA, M. D. and Michihiro OHTANI, M. D. Megumi WATANABE, Ph. D., Ryo MATSUMOTO, Ph. D., Masayoshi TSUTSUMI, Ph. D. and Kazumasa

More information

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,

More information

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45) Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2305(45) 2306(46) THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Dec. Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2307(47) 2308(48) THE JAPANESE

More information

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine

More information

CHEMOTHERAPY Silver sulfadiazine (T 107) CHEMOTHERAPY Fig. 1 Item of patients Table 1 Criteria of bacteriological efficacy by the Committee xcellent: E Score of infection becomes to 0% at the end of medication.

More information

Osamu NEMOTO, M.D. Clinical and Bacteriological Research of Sucrose/ Povidone-Iodine Ointment (U-PASTA kowa) for Pressure Sores and Skin Ulcers Osamu Nemoto Department of Dermatology,Tonan Hosptal

More information

Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic

More information

208 ( 2 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 June 2010 Cefditoren pivoxil (CDTR-PI) MS MS 10%

208 ( 2 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 June 2010 Cefditoren pivoxil (CDTR-PI) MS MS 10% 207 ( 1 ) Cefditoren pivoxil G 2010 2 2 2006 3 Cefditoren pivoxil CDTR-PI MS 10% CDTR-PI 305 2,144 2,006 1,958 1.79% 36 2,006 26 (1.30%) CDTR-PI CDTR-PI (9 mg/kg/day) 1.5 2 (2.70%) 2 (1.92%) 93.5% 1,831

More information

400 CHEMOTHERAPY JAN Table 1 Cases of drop outs

400 CHEMOTHERAPY JAN Table 1 Cases of drop outs VOL. 23 NO. 1 CHEMOTHERAPY 399 Fig. 1 Stracture of cephradine Chemical name : 7-CD(-)-2-amino-2-(1,4-cyclohexadien-1-y1) -acetamido) -3-methyl-8-oxo-5-thia-1-aza- -bicyclo [4. 2. 0] oct-2-ene-2-carboxylic

More information

Key words: Antibodies to Leptospira, Tokyo, Uveitis

Key words: Antibodies to Leptospira, Tokyo, Uveitis Key words: Antibodies to Leptospira, Tokyo, Uveitis Fig. 1 Distribution of Antibody Titers in Age Decade Fig. 3 Distribution of Antibody Titers in each Strain Fig. 2 Correlation between Antibody Titers

More information

Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination

Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination Fig. 1 The value of fungal index and D- arabinitol/creatinine. Fungal index was mesured by Endotoxin D and Endospecy

More information

Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and

More information

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY

More information

1) University Group Diabetes Program: A study of hypoglycemic agents on vascular complica- in patients with adult-onset tions diabetes. I. Design, methods and baseline results. Diabetes 19 (suppl. 2):

More information

VOL. 17 NO. 7 CHEMOTHERAPY 1305 1) W. BRumFirr et al. : Clinical and laboratory studies with carbenicillin. Lancet 1: 1289~ 1293, 1967 2) E. T. KNUDSEN et al. : A new semisynthetic penicillin active against

More information

Clinical studies on Cef triaxone in the field of oral surgery JIRO SASAKI,*1 MASATAKA UEMATSU,*l AKIHIRO KANEKO,*1 YOSHIHIDE OHTA,*1 KAZUO SHIIKI,*2 T

Clinical studies on Cef triaxone in the field of oral surgery JIRO SASAKI,*1 MASATAKA UEMATSU,*l AKIHIRO KANEKO,*1 YOSHIHIDE OHTA,*1 KAZUO SHIIKI,*2 T Clinical studies on Cef triaxone in the field of oral surgery JIRO SASAKI,*1 MASATAKA UEMATSU,*l AKIHIRO KANEKO,*1 YOSHIHIDE OHTA,*1 KAZUO SHIIKI,*2 TAKEFUMI MORIHANA,*3 FUMISADA TOMITA,*3 KEN-ICHI MICHI,*4

More information

Takeji NISHIKAWA, M. D.*, Takashi HARADA, M. D.** and Tatsuya IZUML M. D. Toshiyuki SUGI, M. D. Hiroshi HANYAKU, M. D. Shun-ichi MIYAKAWA, M. D. and Masaru TANAKA, M. D. Nobuko INAMOTO, M. D. and Hironori

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 June 2014 STFX mg mg mg mg mg 1

THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 June 2014 STFX mg mg mg mg mg 1 June 2014 THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 175 29 1 2 2 2 2 2 3 4 4 5 5 2 2 1 2 3 4 5 2014 4 15 STFX 50 mg 10% 2011 8 1 100 mg 1 1 2011 12 2013 5 226 1,186 1,089 1,069 2.11% 23/1,089 1.10% 12/1,089

More information

Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against

More information

1) Kojima H: Culture of ejaculate for Neisseria gonorrhoeae, 1st Serually Transmitted Diseases World Congress, San Juan, 11. 19, 1981. 9) Kojima H, Mori C: Clinical studies on Conococcal and Chlamydial

More information

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega 1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity

More information

特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)

特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案) VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.

More information

28 1 1a 1b 2 MRI T2 3 CT C3 N95 N95 6ml 90

28 1 1a 1b 2 MRI T2 3 CT C3 N95 N95 6ml 90 2015 28 1 89 93 CT C3 Tb PCR XP WBC 7 600/mm 3 CRP 4 08mg/dl MRI MRI CT MRI WBC 9 700/mm 3 CRP 6 09mg/dl CT C3 C2 C7 low density area CT 89 28 1 1a 1b 2 MRI T2 3 CT C3 N95 N95 6ml 90 28 1 4 CT C2 C7 low

More information

東洋医学雑誌

東洋医学雑誌 Vol.61 No.7 924-929, 2010 a b c d Naoki OKADA ad Masaru NATSUAKI b Takashi NISHIMOTO ac Nishimoto Clinic, 2-8-31 Koshienguchi, Nishinomiya, Hyogo 663-8113, Japan Department of Dermatology, Hyogo College

More information

08-g-”O−}„j‹ê-4.02

08-g-”O−}„j‹ê-4.02 200( 96 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 Apr. 585 1 17 MIC 1. (Transtracheal aspiration: TTA) TTA TTA TTA 1400 TTA (diffuse panbronchiolitis, DPB) 1) erythromycin(em) EM 12.5% 87.5% 2,3) EM EM

More information

Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly notified cases of all fo

Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly notified cases of all fo Kekkaku Vol. 79, No. 1: 17-24, 2004 17 (Received 21 Aug. 2003/Accepted 18 Nov. 2003) Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr NTT NTT

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr NTT NTT Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 121 23 7 7 IDSA 122 24 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr. 2012 7 2005 3 10 7 2011 6 2 NTT NTT 2011 6 Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS

More information

Table 1 Classification of female patients with vealcal irritating symptom by their signs Urination pain with other vesical irritability or not Table 2 Serum levels of DL-8280 after a single oral administration

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon

THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis

More information

) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Toky

) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Toky 2.7 2.7.5 1) 199846410-437 2) UTI ( )UTI ( 3 )Chemotherapy (Tokyo) 1986 34408-441 3) () 199745762-778 4) 1992 5) 199543 6) Chemotherapy (Tokyo) 199139687-689 7) Imipenem/Cilastatin sodium (MK-0787/MK-0791)

More information

Some Investigations of Urinary Candidiasis Chujiro YAMAMOTO, M. D., Mitsushi MIZUTANI, M. D. and Tokuro SATO, M. D. From the Department of Urology, Ni

Some Investigations of Urinary Candidiasis Chujiro YAMAMOTO, M. D., Mitsushi MIZUTANI, M. D. and Tokuro SATO, M. D. From the Department of Urology, Ni Title 尿路 Candida 症に於ける 2,3 の検索 Author(s) 山本, 忠治郎 ; 水谷, 三 ; 佐藤, 徳郎 Citation 泌尿器科紀要 (1961), 7(3): 394-405 Issue Date 1961-03 URL http://hdl.handle.net/2433/112109 Right Type Departmental Bulletin Paper Textversion

More information

<95DB8C9288E397C389C88A E696E6462>

<95DB8C9288E397C389C88A E696E6462> 2011 Vol.60 No.4 p.332 338 Usefulness of regional education program for dietary salt reduction: Self-monitoring of urinary salt excretion Kenichiro YASUTAKE[1] Kayoko SAWANO[1] Shoko YAMAGUCHI[1] Hiroko

More information

37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate

37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate 37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5

More information

明海大学歯学雑誌 37‐2/1.秦泉寺

明海大学歯学雑誌 37‐2/1.秦泉寺 J Meikai Dent Med 37, 153 158, 8 153 1 7 5ml /1 min Wong-Baker Face Rating Scale FS 5 1 9. g 3 5ml /1 min, FS 1 66 6ml /1 min FS 5 1 9. g 3 6ml /1 min, FS 3 Two Cases of Xerostomia that Showed an Improvement

More information

東洋医学雑誌

東洋医学雑誌 Vol.67 No.2 123-130, 2016 Akiyo GUSHI a Chihaya KORIYAMA b Ryo YOSHINAGA c Hiromi YANO c Junichi TSUMAGARI d Eiichi TAHARA c a Gushi Dermatological Clinic, 45-3 Higashiohsyoji, Satsumasendai city, Kagoshima

More information

indd

indd 12 61 1 2011 原著 1)2)5) 1) 1)2) 1)2)5) 1)3)5) 1)2) 1)2)5) 1)2) 1)2) 2) 2) 4) 1) 1) 2) 3) 4) 5) 2010 10 6 2010 12 6 A Comparative Study of the Effect and Discomfort Produced by Pharyngeal Anesthesia with

More information

小児感染免疫第25巻第2号

小児感染免疫第25巻第2号 Vol. 25No. 2145 1,2 1 1 1 1 2 2 2 TFLX 9 TFLX 450 mg16.6 mgkg TFLX 30 kg TFLX 2009 10 TFLX 1 1 2 3,4 TFLX 9 22 6 18 19 TFLX 450 mg150 mg 1 1 1 3 16.6 mgkg 20 20 0 21 3 135.0 cm0.1 S.D. 27.0 kg0.8 S.D.

More information

日本消化器外科学会雑誌第29巻第9号

日本消化器外科学会雑誌第29巻第9号 Table 1 Oligonucleotide primers used for RT-PCR and internal probes used for Southern blot hybridization Cytokine Primer Sequence (5'-3') 5' 3' Internal probe s' 3' Internal probe 5' 3' Internal probe

More information

Web Stamps 96 KJ Stamps Web Vol 8, No 1, 2004

Web Stamps 96 KJ Stamps Web Vol 8, No 1, 2004 The Journal of the Japan Academy of Nursing Administration and Policies Vol 8, No 1, pp 43 _ 57, 2004 The Literature Review of the Japanese Nurses Job Satisfaction Research Which the Stamps-Ozaki Scale

More information

Special IssueDiagnoses and therapeutic agents for age-related diseases Reviews Original Case reports β Medicinal drugs affecting on clinical laboratory blood test results and adverse effects of them

More information

38 38 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 1 Feb CT A B A CT B 20xx 2 8 LAM 20xx 1 12 CT S6, S10 Aspergillus spp. Micafungin MCFG 150 mg/ I

38 38 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 1 Feb CT A B A CT B 20xx 2 8 LAM 20xx 1 12 CT S6, S10 Aspergillus spp. Micafungin MCFG 150 mg/ I Feb. 2013 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 1 37 37 Liposomal amphotericin B 1 2 2 2 1 1 1 2 1 1 2 2012 12 25 33 Lymphangioleiomyomatosis: LAM 2 20xx 1 CT Aspergillus spp. Micafungin MCFG Itraconazole

More information

Fig.1 Chemical structure of BAY o 9867

Fig.1 Chemical structure of BAY o 9867 Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985

More information

Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det

Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not detected *: time after last administration Table 2. Concentration

More information

Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis

Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis growth was monitored at 660 nm with a biophotorecorder. Table 1.Relative inhibitory effects of fatty acids,plant oils,

More information

04-c-„FŒ{›xŒ¾-4.01

04-c-„FŒ{›xŒ¾-4.01 544( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 2. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 545( 57 ) 9 5 2003 8 2004 714 565 719 50 20 39 0 9 70 79 44.4 91.7% Escherichia coli

More information

BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI

BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI 20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old

More information

202

202 201 Presenteeism 202 203 204 Table 1. Name Elements of Work Productivity Targeted Populations Measurement items of Presenteeism (Number of Items) Reliability Validity α α 205 α ä 206 Table 2. Factors of

More information

CHEMOTHERAPY Table 2 Clinical response of 6059-S by infection Table 3 Effect of 6059-S on blood chemistry *Normal range : S-GOT 20 `60 mu/ml, S-GPT 5 `25 IU/L, Al-Pase 30 `85 mu/ml In oilier cases : S-GOT

More information